Penumbra Announces Key Events At Society Of Interventional Radiology 2017 Meeting

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today announced key events at the upcoming Society of Interventional Radiology 2017 meeting (SIR 2017) to be held March 4-9 at the Washington Convention Center in Washington, D.C. These events include results of a single-center study of the company’s Indigo^® System, in-booth presentations and workshop demonstrations of the company’s peripheral vascular products for thrombectomy and embolization.

“Rapid Reperfusion from Mechanical Aspiration Thrombectomy is Superior to Slow Infusion of Intra-Arterial Thrombolytics in Patients with Confirmed Peripheral or Visceral Arterial Occlusions”

Corey Teigen, M.D., Sanford Health, Fargo, ND, will share results of a study of 43 patients comparing use of mechanical thrombectomy by aspiration using the Indigo System to intra-arterial thrombolytics in patients with peripheral or visceral arterial occlusions or emboli. “Rapid Reperfusion from Mechanical Aspiration Thrombectomy is Superior to Slow Infusion of Intra-Arterial Thrombolytics in Patients with Confirmed Peripheral or Visceral Arterial Occlusions” (abstract #253) will be presented during the Thromboembolic Disease and Lysis scientific session (SS27) on Tuesday, March 7 from 3-3:09 p.m. in Room 150A.

Attendees will have the opportunity to learn more about Penumbra’s Indigo System, Ruby^® Coil, POD^® System and LANTERN^® devices, as well as the Penumbra System^®, at the following events:

• Dr. Teigen will also present the results of a subset of 67 patients in the Aneurysm Coiling Efficiency (ACE) Study at Penumbra Booth #541 on Tuesday, March 7 at 10 a.m. The goal of this multi-center study was to collect long-term outcomes of aneurysms and vessels embolized utilizing soft, large volume coils to achieve high packing density.
• A dinner symposium on Tuesday, March 7 at 6:30 p.m. at the Archives Room at the Marriott Marquis. James Benenati, M.D., Miami Cardiac and Vascular Institute, FL, and Parag Patel, M.D., Medical College of Wisconsin, will share their experience with Penumbra’s peripheral vascular products.
• Three in-booth sessions at Penumbra Booth #541 on Monday, March 6, and Tuesday, March 7, will provide attendees with opportunities to hear from physician experts regarding the application of Penumbra’s peripheral technologies in their practice.
• Four workshops will offer attendees additional discussion opportunities with experienced users and hands-on experience with Penumbra embolization and thrombectomy products in simulated models: Atherectomy & Thrombectomy (Location – HO08) and Catheters & Microcatheters (Location – HO01) Workshop on Sunday, March 5; Coils and Plugs (Location – HO02) Workshop on Tuesday, March 7; and IVC Filters (Location – HO10) on Wednesday, March 8.
• Penumbra’s aspiration-based thrombectomy system for acute ischemic stroke revascularization will be featured during the day-long SIR: The Stroke Course on Thursday, March 9 in Room 151AB. The course includes hands-on workshops with the Penumbra System with ACE ^TM 68 Reperfusion Catheter.

About Penumbra’s Peripheral Vascular Products

Penumbra has a growing suite of thrombectomy and embolization products for use in a range of peripheral vascular conditions:

• The Indigo System is a next-generation continuous aspiration thrombectomy device designed for the removal of fresh, soft emboli and thrombi from the peripheral venous and arterial systems, and includes four catheter sizes (CAT 3, 5, 6 and 8). The aspiration lumen is paired with a proprietary continuous vacuum aspiration pump to evacuate clot. The Indigo System’s proprietary Separator^TM technology enables unobstructed aspiration for the duration of the procedure. The Indigo System, received 510(k) clearance in May 2015 to remove clots from the peripheral venous system, and it is one of the newest interventional advancements designed specifically to help physicians remove DVTs.
• Penumbra’s embolization platform includes RUBY^® Coil; POD^® (Penumbra Occlusion Device), designed specifically to occlude peripheral vessels; and POD Packing Coil, which is uniquely designed to pack very densely behind Ruby and POD to occlude arteries and veins throughout the peripheral vasculature, including aneurysms.
• The LANTERN microcatheter is designed to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic devices, such as occlusion coils, to the peripheral vasculature. It is offered in a variety of lengths and tip shapes.

About Penumbra System

The Penumbra System enables physicians to use aspiration, which acts like a minimally invasive “vacuum” inside the artery, to remove stroke-causing blood clots from the brain. The Penumbra System is the only FDA-cleared integrated aspiration system for the revascularization of acute ischemic stroke patients with large vessel occlusions.

Important Safety Information

Additional information about Penumbra’s products can be located on Penumbra’s website at http://www.penumbrainc.com/healthcare-professionals. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on interventional therapies that designs, develops, manufactures and markets innovative devices. The company has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc. Penumbra, the Penumbra logo, Indigo, Ruby, POD, LANTERN, Pump MAX, Penumbra System and ACE are trademarks of Penumbra, Inc. Other trademarks are the property of their respective owners.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2016. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Source: Penumbra, Inc.